0A8U Stock Chart & Stats
$1.16
$0.00(0.00%)
At close: 4:00 PM EST
$1.16
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $1.80
Previous CloseN/A
Volume0.00
Average Volume (3M)411.00
Market Cap
$14.04M
Enterprise Value$4.96
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,696,641
10 Day Avg. Volume231
30 Day Avg. Volume411
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Merger With Caldera And $278M Concurrent FinancingA binding all-stock merger and a $278M institutional financing materially lengthen Synlogic’s cash runway and de-risk near-term financing. This structural funding supports planned Phase 2 development, enabling multi-year clinical programs and reducing execution risk tied to interim capital markets.
No Reported Debt On Balance SheetZero reported debt lowers fixed financial commitments and interest expense, preserving flexibility to allocate capital to R&D. Over the medium term this reduces default risk and allows management to prioritize clinical investment over debt servicing, a durable balance-sheet strength.
Sharply Reduced Operating Losses And Cash BurnDramatic reduction in cash burn and narrowing losses reflect sustained cost discipline and program prioritization. This structural improvement lowers ongoing financing needs, enhances survival odds through clinical milestones, and increases optionality for strategic partnerships or value-creating development.
Bears Say
Essentially No Recurring RevenueThe company remains pre-revenue and dependent on clinical progress and external capital to create commercial cash flow. Lack of recurring revenue makes long-term viability contingent on successful trials, regulatory approvals, and commercialization—structural risks for biotech developers.
Negative Free Cash Flow And Continued Funding DependenceDespite burn improvement, free cash flow is negative and volatile (TTM FCF growth -23.8%). This structural reliance on external financing raises dilution and execution risk across clinical timelines, constraining long-term strategic choices absent consistent cash generation.
Limited Ownership Stake For Synlogic Shareholders In Combined EntityThe expected ~2.3% holding on closing means existing shareholders will have minimal influence and diluted exposure to upside. This structural dilution reduces shareholder alignment and limits the economic benefit from future value creation within the combined company.
Synlogic News
0A8U FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest share price was $0.54 and its highest was $1.79 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $14.04M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,696,641 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in GB:0A8U
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―